Astec LifeSciences has reported strong revenue growth in Q3 FY26, driven by higher Enterprise volumes and a surge in Contract Manufacturing (CDMO) offtake.

 

The company’s total income jumped 31% year-on-year to Rs 125.5 crore, up from Rs 95.8 crore in Q3 FY25. Sequentially, revenue soared 1.7 times over Q2 FY26, underlining the momentum in its CDMO business.

 

Earnings turned positive as well, with EBITDA rising to Rs 4.8 crore in Q3 FY26, compared with a negative Rs 3.8 crore in the same period last year. Profit before exceptional items and tax narrowed losses to Rs 13.6 crore from Rs 25.1 crore, while net loss after tax came in at Rs 15.7 crore, down sharply from Rs 40.4 crore in Q3 FY25.

 

Commenting on the performance, Chairman N B Godrej said: "Astec delivered strong revenue growth, recording 1.3x growth over Q3 FY25 on the back of higher Enterprise volumes and improved offtake in the Contract Manufacturing segment. 

 

"Sequentially, revenue increased 1.7x over Q2 FY26, primarily driven by CDMO offtake. Improvement in Enterprise margins, together with higher CDMO volume offtake, contributed significantly to the overall margin improvement, resulting in a positive EBITDA of Rs.4.8 crore in Q3 FY26."

 

Segment performance highlights:

 

1. Enterprise business: Rs 46.6 crore, up 36.7% YoY

 

2. Contract Manufacturing & New Products: Rs 77.6 crore, up 29.7% YoY

 

3. Exports: Rs 86.3 crore, up 23.9% YoY

 

4. Domestic revenue: Rs 37.9 crore, up 55.9% YoY

 

For the nine-month period, Astec recorded total income of Rs 292 crore, a 9.5% increase over 9M FY25, with both domestic and export markets contributing to growth.